The disease of interest was cancer and the biological samples were serum from women with HER2/Erb2-positive primary breast cancer, plasma from non-small cell lung cancer patients and plasma from healthy controls (Table 1). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.